Hamps Bio Reports H1 FY27 Standalone PAT Turnaround to ₹19.76 Lakh vs ₹19.55 Lakh Loss YoY
Hamps Bio Ltd announced its unaudited standalone and consolidated financial results for the half year ended September 30, 2026. Standalone revenue from operations grew 48.8% YoY to ₹593.89 lakh compared to ₹399.15 lakh in the half year ended September 30, 2025. The company delivered a turnaround in standalone net profit to ₹19.76 lakh, reversing from a net loss of ₹19.55 lakh in the previous corresponding period. On a consolidated basis, segment revenue reached ₹769.08 lakh, led by ₹552.86 lakh from Freeze Dried Products and ₹216.22 lakh from Pharma Products.
உச்சம் நம்பிக்கை
என்ன மாறியதுHamps Bio swung to profitability in H1 FY27 with a net profit of ₹19.76 lakh alongside a 48.8% YoY standalone revenue increase.
ஏன் இது முக்கியம்The company reversed previous half-yearly operational losses, supported by revenue scale and diversification into Freeze Dried Products following its subsidiary acquisition.
Standalone Revenue (H1 FY27): ₹593.89 லட்சம்Standalone PAT (H1 FY27): ₹19.76 லட்சம்Consolidated Segment Revenue (Total): ₹769.08 லட்சம்Freeze Dried Segment Revenue: ₹552.86 லட்சம்
📅 குறுகிய காலம்The turnaround into positive net income and top-line growth could provide positive sentiment in upcoming trading sessions.
📈 நீண்ட காலம்The expansion into freeze-dried manufacturing via the acquired subsidiary represents the primary structural driver, though scale remains relatively modest.
⚠ அபாய எச்சரிக்கைகள்
- Small profit base prone to quarterly volatility
- Freeze Dried segment profitability is not independently disclosed
👀 கவனிக்க வேண்டியவை
Monitor whether profitability sustains in the second half of the year and observe revenue contribution from newly consolidated subsidiary HSDL Innovative Private Limited.
